Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak (michal.masternak@ucf.edu) for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 9, Number 3, 2004

The preliminary evaluation of conformal hypofractionated radiotherapy (3D) toxicity in prostate cancer patients

Piotr Pęczkowski, Małgorzata Pilichowska, Tomasz Demkow

Summary:

Purpose: The purpose of this retrospective study was to evaluate the degree of acute and late genitourinary (GU) and gastrointestinal (GI) toxicity of conformal hypofractionated radiotherapy (3DRTH) in prostate cancer patients.
Material and methods: From January 1998 to July 2000, 137 (T1-T3NxM0) patients were treated with combine therapy: neoadjuvant hormonal therapy not less then 3 months and 3DRTH. The median follow-up was 20 (range 6-43) months. The degree of acute and late GI and GU toxicity was graded according RTOG/EORTC scale. A 3D technique was developed. We used 4 MV and 15 MV photon beams treating all fields (3 field -blocks or MLC) 5 days a week with 2.6 Gy per fraction to a total dose of 52 Gy to the prostate. Results: Acute GU toxicity: lack - 34 (25%), I - 90 (65%), II - 12 (9%), III - 1 (1%). Late GU toxicity: lack - 128 (94 %), I - 6 (4%), II - 2 (1.5%), III - 1 (0.5%). Acute GI toxicity: lack - 77 (56 %), I - 55 (40%), II - 5 (4%), III - 0. Late GI toxicity: lack - 129 (94%), I - 8 (6%), II - 0, III -0.
Conclusions: The hyperfractionated radiotherapy schedule for localized prostate cancer seems to be a safe method of irradiation. Dose escalation should also be considered.

Signature: Rep Pract Oncol Radiother, 2004; 9(3) : 77-80

FULL TXT (PDF: 0,11MB)

« back

 
INDEXED IN:

Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.

http://www.sciencedirect.com/science/journal/15071367/19/2